LifeStance Health Group Inc is a mental healthcare company that operates as a provider of outpatient mental health services, spanning psychiatric evaluations and treatment, psychological and neuropsychological testing, and individual, family, and group therapy. It treats a broad range of mental health conditions, including anxiety, depression, bipolar disorder, eating disorders, psychotic disorders, and post-traumatic stress disorder, using evidence-based approaches to ensure effective treatment. The group has a single operating and reportable segment of mental health services.
Last trade$14.26
Day change-$0.225 (-1.55%)
Day range$14.16 – $14.77
Volume1,912,909
Market cap$5.51B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$5.51B
Price / earnings
76.56×
Price / book
3.69×
Price / sales
3.28×
EV / sales
3.3×
EV / EBITDA
35.02×
Profitability
Earnings per share
$0.19
Return on assets
3.29%
Return on equity
4.82%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.17×
Current ratio
1.44×
Quick ratio
1.44×
Cash ratio
0.84×
Cash flow
Price / cash flow
24.19×
Price / free cash flow
30.71×
Free cash flow
$179.27M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for LFST, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$455.86M
$435.35M
$403.48M
$382.2M
$363.81M
$345.31M
$332.97M
$325.48M
Cost of revenue
$294.46M
$282.31M
$267.54M
$255.9M
$247.23M
$236.88M
$223.18M
$216.04M
Gross profit
$161.4M
$153.04M
$135.93M
$126.3M
$116.58M
$108.43M
$109.79M
$109.44M
Selling, general and administrative
$113.39M
$108.14M
$100.33M
$94.78M
$95.62M
$97.38M
$94.43M
$93.71M
Research and development
$0
$0
$0
$0
$0
$0
$0
$0
Total operating expenses
$128.84M
$122.83M
$114.37M
$108.33M
$109.17M
$111.38M
$108.19M
$109.57M
Operating income
$32.57M
$30.21M
$21.56M
$17.96M
$7.41M
-$2.95M
$1.6M
-$131K
Interest expense
-$2.49M
-$2.63M
-$1.79M
-$2.88M
-$2.81M
-$2.9M
-$3.07M
-$9.4M
Income before taxes
$27.4M
$27.46M
$19.76M
$15.2M
$4.57M
-$5.94M
-$1.47M
-$8.88M
Income taxes
$5.02M
$3.85M
$5.52M
$3.54M
$3.5M
-$2.15M
-$2.18M
-$1.76M
Net income
$22.39M
$23.61M
$14.24M
$11.67M
$1.08M
-$3.79M
$709K
-$7.11M
Net income attributable to common shareholders
$22.39M
$23.61M
$14.24M
$11.67M
$1.08M
-$3.79M
$709K
-$7.11M
EBITDA
$47.5M
$44.46M
$34.88M
$31.4M
$20.97M
$11.06M
$15.36M
$14.54M
Basic earnings per share
$0.06
$0.06
$0.04
$0.03
$0.00
-$0.01
$0.00
-$0.02
Diluted earnings per share
$0.06
$0.06
$0.04
$0.03
$0.00
-$0.01
$0.00
-$0.02
Recent news
Company coverage with links to the original publishers.
LifeStance Health Group has received a Zacks Rank #2 (Buy) rating due to strong earnings estimate revisions. The company's current-quarter EPS estimate increased 33.3% year-over-year to $0.04 per share, while full-year estimates surged 750% to $0.17 per share. Analysts have shown consistent agreement in raising estimates over the past month, and the stock has already gained 10.9% in the past four weeks.
LifeStance Health Group (LFST) is highlighted as a strong momentum stock with a Zacks Rank #2 (Buy) rating and Momentum Style Score of A. The outpatient mental health services provider has outperformed its industry and the broader market, with shares up 114.88% over the past year compared to the S&P 500's 9.35% gain. Recent positive earnings estimate revisions and strong price momentum across multiple timeframes support the bullish outlook.
LifeStance Health Group (LFST) reported Q3 2026 earnings of $0.06 per share, doubling the consensus estimate of $0.03, with revenues of $455.86 million exceeding expectations by 6.31%. The stock has gained 101.9% year-to-date, significantly outperforming the S&P 500's 12.3% gain. However, the company received a Zacks Rank #3 (Hold) rating with mixed estimate revisions, suggesting near-term performance in line with the market.
LifeStance Health Group announced Q3 2026 financial results with revenue of $455.9 million, up 25% year-over-year, and net income of $22.4 million compared to $1.1 million in Q3 2025. The company raised its full-year 2026 guidance across all metrics, including revenue to $1.741-$1.761 billion and Adjusted EBITDA to $242-$250 million. The clinician base grew 11% to 8,863, and visit volumes increased 17% to 2.7 million.
Zacks highlights strong stock performance from its research methodologies, with HF Sinclair surging 49% after a Rank upgrade and FirstCash gaining 36.3% since the 2026 Top 10 list launch. The article reviews market conditions showing a shift toward value stocks amid inflation concerns and elevated Treasury yields, while showcasing performance of various Zacks portfolios including the Focus List, ECAP, and ECDP.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.